Tenecteplase: Supply issue closed
There is a global supply issue affecting tenecteplase (a hospital-only medicine).
25 August 2022 update
Boehringer Ingelheim now has sufficient stock of tenecteplase to supply the New Zealand market.
Stock is being allocated by Boehringer Ingelheim to ensure equitable supply of tenecteplase throughout the market, as the global shortage of this medicine continues.
About this issue
The supplier of tenecteplase, Boehringer Ingleheim, has informed Pharmac that there are limited supplies available to cover demand through 2022.
Pharmac has not been able to source another brand of tenecteplase.
We have received clinical advice that alteplase is an appropriate alternative. There is enough stock of alteplase to manage any change in usage.
The Stroke Network and Ministry of Health have:
- circulated advice on the use of tenecteplase and alteplase to DHBs (letter dated 28 Jan 2021)
- provided an update on supply of tenecteplase (letter dated 18 Feb 2021).
Download the advice from the Stroke Network and Ministry of Health
- 2020 02 18 Tenecteplase Supply Update letter [PDF 330 KB]
- 2021 01 28 Cross agency letter re Tenecteplase stock issue [PDF 315 KB]